We are live on ! Find out more
VOR icon

Vor Biopharma
VOR

80 hedge funds and large institutions have $717M invested in Vor Biopharma in 2026 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

289% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 9

189% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 9

143.14% more ownership

Funds ownership: 245.39% → 388.53% (+143%)

116% more capital invested

Capital invested by funds: $332M → $717M (+$385M)

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

45% more funds holding

Funds holding: 55 → 80 (+25)

73% less call options, than puts

Call options by funds: $919K | Put options by funds: $3.41M

Holders
80
Holders Change
+25
Holders Change %
+45.45%
% of All Funds
0.98%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
35
Increased
26
Reduced
9
Closed
9
Calls
$919K
Puts
$3.41M
Net Calls
-$2.49M
Net Calls Change
-$12.7M

Top Buyers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
+$80M
2
Marshall Wace
Marshall Wace
United Kingdom
+$16.3M
3
VA
VR Adviser
New York
+$15.5M
4
State Street
State Street
Massachusetts
+$14.5M
5
CP
Caligan Partners
New York
+$14.1M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.9M
2
Citadel Advisors
Citadel Advisors
Florida
-$4.02M
3
FCM
Findell Capital Management
New York
-$3.02M
4
Ameriprise
Ameriprise
Minnesota
-$2.13M
5
SFM
Sphera Funds Management
Israel
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$4.61M +$480K +34,053 +15%
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$4.15M +$3.07M +217,789 +1,470%
VFT
28
Vanguard Fiduciary Trust
Pennsylvania
$3.31M +$2.62M +185,511 New
JF
29
Jump Financial
Illinois
$3.09M +$2.44M +173,028 New
Tudor Investment Corp
30
Tudor Investment Corp
Connecticut
$2.72M -$213K -15,102 -9%
Citadel Advisors
31
Citadel Advisors
Florida
$2.65M -$4.02M -285,126 -66%
Renaissance Technologies
32
Renaissance Technologies
New York
$2.3M +$1.82M +128,839 New
Morgan Stanley
33
Morgan Stanley
New York
$2.08M +$1.24M +88,258 +310%
Bank of America
34
Bank of America
North Carolina
$2.01M +$1.59M +112,496 +28,408%
AI
35
Axiom Investors
Connecticut
$1.71M +$1.35M +95,745 New
QC
36
Quadrature Capital
United Kingdom
$1.37M +$703K +49,839 +186%
Jane Street
37
Jane Street
New York
$1.35M -$225K -15,920 -17%
Northern Trust
38
Northern Trust
Illinois
$1.15M +$361K +25,603 +66%
JJ
39
Johnson & Johnson
New Jersey
$959K – – –
SAM
40
Simplify Asset Management
Nevada
$955K +$755K +53,510 New
Rafferty Asset Management
41
Rafferty Asset Management
New York
$901K +$712K +50,505 New
BHCM
42
Brevan Howard Capital Management
Jersey
$753K +$595K +42,217 New
ICM
43
Irenic Capital Management
New York
$583K +$461K +32,663 New
EGM
44
Engineers Gate Manager
New York
$480K -$18.7K -1,324 -5%
Squarepoint
45
Squarepoint
New York
$455K +$99K +7,023 +38%
SCM
46
Sarissa Capital Management
Connecticut
$453K – – –
BG
47
Bollard Group
Massachusetts
$428K – – –
Charles Schwab
48
Charles Schwab
California
$396K +$313K +22,216 New
PA
49
Profund Advisors
Maryland
$393K +$310K +22,015 New
SRL
50
Scientech Research LLC
New Jersey
$268K +$212K +15,047 New
1
2
3 4

VOR Hedge Fund Activity: Q1 2026 in Review

80 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q1 2026, worth a combined $717M — up 116% from $332M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new VOR positions and 9 closed out — a net gain of 26 holders — while 26 added to existing stakes and 9 trimmed.

The largest buyer was TCG Crossover Management, opening a new position worth an estimated $80M. The largest seller was Fidelity Investments, cutting an estimated $13.9M.

  • 80 institutional investors held Vor Biopharma (VOR) as of Q1 2026, up from 55 in Q4 2025.
  • Funds reported $717M of Vor Biopharma stock for Q1 2026, up 116% quarter-over-quarter.
  • 35 funds opened new Vor Biopharma positions in Q1 2026 and 9 closed out, a net change of +26 holders.
  • The largest Vor Biopharma buyer in Q1 2026 was TCG Crossover Management, an estimated $80M added.
  • The largest Vor Biopharma seller in Q1 2026 was Fidelity Investments, an estimated $13.9M sold.

Based on aggregated 13F filings for Q1 2026.